Literature DB >> 7901781

Diminution of dopaminergic neurons in the substantia nigra of sporadic amyotrophic lateral sclerosis.

S Kato1, M Oda, H Tanabe.   

Abstract

The substantia nigra was examined immunohistochemically using the antibody to tyrosine hydroxylase in 15 patients with sporadic amyotrophic lateral sclerosis (ALS). The number of dopaminergic neurons was diminished in the substantia nigra of seven cases. The diminution was not related to the age, duration of the illness or use of respirators. Supranuclear ophthalmoplegia developed in four and dementia in three out of seven patients with reduction of nigral dopaminergic neurons. In addition, five out of the seven patients developed respiratory failure within 2 years after the onset of the illness. The nigral dopaminergic system may be involved in rapidly progressive ALS patients with supranuclear ophthalmoplegia and/or dementia.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7901781     DOI: 10.1111/j.1365-2990.1993.tb00444.x

Source DB:  PubMed          Journal:  Neuropathol Appl Neurobiol        ISSN: 0305-1846            Impact factor:   8.090


  14 in total

Review 1.  The neuropathological signature of bulbar-onset ALS: A systematic review.

Authors:  S Shellikeri; V Karthikeyan; R Martino; S E Black; L Zinman; J Keith; Y Yunusova
Journal:  Neurosci Biobehav Rev       Date:  2017-02-02       Impact factor: 8.989

Review 2.  Cerebral Iron Deposition in Neurodegeneration.

Authors:  Petr Dusek; Tim Hofer; Jan Alexander; Per M Roos; Jan O Aaseth
Journal:  Biomolecules       Date:  2022-05-17

3.  Topographic involvement of the striatal efferents in basal ganglia of patients with adult-onset motor neuron disease with basophilic inclusions.

Authors:  H Ito; H Kusaka; S Matsumoto; T Imai
Journal:  Acta Neuropathol       Date:  1995       Impact factor: 17.088

Review 4.  Parkinsonism in motor neuron disease: case report and literature review.

Authors:  T L Williams; P J Shaw; J Lowe; D Bates; P G Ince
Journal:  Acta Neuropathol       Date:  1995       Impact factor: 17.088

5.  Parkinson's disease-like midbrain hyperechogenicity is frequent in amyotrophic lateral sclerosis.

Authors:  Panteha Fathinia; Andreas Hermann; Ulrike Reuner; Jan Kassubek; Alexander Storch; Albert C Ludolph
Journal:  J Neurol       Date:  2012-08-26       Impact factor: 4.849

6.  The parkinsonian neurotoxin rotenone activates calpain and caspase-3 leading to motoneuron degeneration in spinal cord of Lewis rats.

Authors:  S Samantaray; V H Knaryan; M K Guyton; D D Matzelle; S K Ray; N L Banik
Journal:  Neuroscience       Date:  2007-03-23       Impact factor: 3.590

7.  Extrapyramidal deficits in ALS: a combined biomechanical and neuroimaging study.

Authors:  Maryse Feron; Annabelle Couillandre; Eya Mseddi; Nicolas Termoz; Malek Abidi; Eric Bardinet; Daniel Delgadillo; Timothée Lenglet; Giorgia Querin; Marie-Laure Welter; Nadine Le Forestier; François Salachas; Gaelle Bruneteau; Maria Del Mar Amador; Rabab Debs; Lucette Lacomblez; Vincent Meininger; Mélanie Pélégrini-Issac; Peter Bede; Pierre-François Pradat; Giovanni de Marco
Journal:  J Neurol       Date:  2018-07-11       Impact factor: 4.849

8.  Dopamine transporter immunoreactivity in peripheral blood lymphocytes discriminates Parkinson's disease from essential tremor.

Authors:  C Pellicano; F R Buttarelli; A Circella; D Tiple; M Giovannelli; D Benincasa; C Colosimo; F E Pontieri
Journal:  J Neural Transm (Vienna)       Date:  2007-01-29       Impact factor: 3.850

9.  The dopaminergic system in peripheral blood lymphocytes: from physiology to pharmacology and potential applications to neuropsychiatric disorders.

Authors:  Francesca R Buttarelli; Alessandra Fanciulli; Clelia Pellicano; Francesco E Pontieri
Journal:  Curr Neuropharmacol       Date:  2011-06       Impact factor: 7.363

10.  α-synuclein interacts with SOD1 and promotes its oligomerization.

Authors:  Anika M Helferich; Wolfgang P Ruf; Veselin Grozdanov; Axel Freischmidt; Marisa S Feiler; Lisa Zondler; Albert C Ludolph; Pamela J McLean; Jochen H Weishaupt; Karin M Danzer
Journal:  Mol Neurodegener       Date:  2015-12-08       Impact factor: 14.195

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.